University of PittsburghPittsburgh, Pennsylvania, United States
Disclosure(s): No financial relationships to disclose
209 - Population Pharmacokinetics of Meropenem-Vaborbactam in Acutely Ill Hospitalized Patients with Various Degrees of Renal Dysfunction
Thursday, October 17, 20243:45 PM – 4:00 PM US PT
311 - Defining the magnitude of desirability of outcome ranking (DOOR) differences in effectiveness of Ceftazidime-Avibactam (CZA) versus Ceftolozane-Tazobactam (C/T) for multidrug-resistant (MDR) Pseudomonas aeruginosa infections in the United States (CACTUS)
Friday, October 18, 202410:42 AM – 10:54 AM US PT
312 - Impact of Patient Subgroups on the Efficacy of Ceftazidime-Avibactam (CZA) versus Ceftolozane-Tazobactam (C/T) for Multidrug-resistant (MDR) Pseudomonas aeruginosa infections in the United States (CACTUS)
Friday, October 18, 202410:54 AM – 11:06 AM US PT
